Results 271 to 280 of about 78,184 (307)

Synergistic disruption of BTK and BCL-2 causes apoptosis while inducing ferroptosis in double-hit lymphoma.

European Journal of Pharmacology, 2023
Double-hit lymphoma (DHL) is an aggressive subset of Diffuse Large B-cell Lymphoma (DLBCL) with poor outcomes and without satisfying treatment options. BTK inhibitor monotherapy is ineffective to suppress aggressive lymphoma.
S. A. Setiawan, Winston Liu, Pei-Wei Weng, Chia-Hwa Lee, Vijesh Kumar Yadav, M. Hardianti, C. Yeh, T. Chao   +7 more
semanticscholar   +1 more source

Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy.

European journal of medicinal chemistry, 2023
Bruton's Tyrosine Kinase (BTK) functions as a key regulator of B-cell receptor (BCR) signaling pathway, which is frequently hyperactivated in a variety of lymphoma cancers.
Song Chen, Zhendong Chen, Lixue Lu, Yunpeng Zhao, Rong-Han Zhou, Qiong Xie, Yongzhi Shu, Jun Lin, Xufen Yu, Yonghui Wang   +9 more
semanticscholar   +1 more source

On-Target BTK Mutations Promote Resistance to Noncovalent BTK Inhibitors

Cancer Discovery, 2022
Abstract Resistance to noncovalent BTK inhibitors is mediated by non-C481 BTK and PLCγ2 mutations.
openaire   +2 more sources

BTK inhibitors: past, present, and future.

TIPS - Trends in Pharmacological Sciences
Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment landscape for B cell lymphomas such as chronic lymphocytic leukemia (CLL). The first-in-class BTK inhibitor ibrutinib has recently been succeeded by covalent BTK inhibitors that ...
Allison Cool, Tiffany Nong, S. Montoya, Justin Taylor   +3 more
semanticscholar   +1 more source

Cardiotoxicity of BTK inhibitors: ibrutinib and beyond

Expert Review of Hematology, 2022
Introduction The development of Brutons Tyrosine Kinase (BTK) inhibitors has transformed the treatment of B-cell malignancies and other non-malignant conditions. Management of the unique cardiotoxic profile of these agents requires prompt recognition and
Bradley W Christensen, V. G. Zaha, F. Awan   +2 more
semanticscholar   +1 more source

Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.

European journal of medicinal chemistry, 2021
Therapy based on Bruton's tyrosine kinase (BTK) inhibitors one of the major treatment options currently recommended for lymphoma patients. The first generation of BTK inhibitor, Ibrutinib, achieved remarkable progress in the treatment of B-cell ...
Jiakuo Liu, Chengjuan Chen, Dongmei Wang, Jie Zhang, Tiantai Zhang   +4 more
semanticscholar   +1 more source

Recent development of BTK-based dual inhibitors in the treatment of cancers.

European journal of medicinal chemistry, 2022
Bruton's tyrosine kinase (BTK) is a promising target in the treatment of various cancers. Despite the early success of BTK inhibitors in the clinic, these single-target drug therapies have limitations in their clinical applications, such as drug ...
Fansheng Ran, Yun Liu, Zhongyuan Xu, Chi Meng, Dezhi Yang, Jianqiang Qian, X.‐T. Deng, Yanan Zhang, Yong Ling   +8 more
semanticscholar   +1 more source

Next-generation Bruton's tyrosine kinase (BTK) inhibitors potentially targeting BTK C481S mutation- Recent developments and Perspectives.

Current Topics in Medicinal Chemistry, 2022
Bruton's tyrosine kinase (BTK) plays a vital role in B-cell antigen receptor (BCR) signalling transduction pathway. Controlling BCR signalling by BTK inhibitors is a promising therapeutic approach for the treatment of inflammatory and autoimmune diseases.
Debasis Das, Jingbing Wang, Jiann-Ruey Hong   +2 more
semanticscholar   +1 more source

Development of btk Transgenic Mice

1995
B cell development is characterized by the orderly expression of cell surface markers and responses to specific activation signals [1]. Tyrosine kinases are involved in signalling pathways that regulate these events [2]. Bruton’s tyrosine kinase (Btk) is a tyrosine kinase expressed in B and myeloid cells [3,4].
E A, Faust, D J, Rawlings, D C, Saffran, O N, Witte   +3 more
openaire   +2 more sources